Scinai Immunotherapeutics (SCNI) Return on Equity (2020 - 2023)

Scinai Immunotherapeutics has disclosed Return on Equity across 4 years of filings, most recently posting 0.03% for Q1 2023.

• Return on Equity for Q1 2023 came in at 0.03%, down 41.0% year-over-year; the trailing twelve-month figure through Mar 2023 was 0.03% (down 41.0% YoY), and the FY2025 annual result was 0.01%, up 2.0% from the prior year.
• Return on Equity came in at 0.03% for Q1 2023 at Scinai Immunotherapeutics, up from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.44% in Q1 2022 to a low of 0.04% in Q3 2020.
• The 4-year median for Return on Equity is 0.01% (2022), against an average of 0.07%.
• Across the five-year window, Return on Equity climbed 6 bps in 2021 and plunged 41 bps in 2023, its largest moves.
• Scinai Immunotherapeutics' Return on Equity stood at 0.03% in 2020, then jumped by 191 bps to 0.03% in 2021, then tumbled by 101 bps to 0.0% in 2022, then soared by 7474 bps to 0.03% in 2023.
• The last three Return on Equity figures came in at 0.03% (Q1 2023), 0.0% (Q4 2022), and 0.44% (Q1 2022), per Business Quant data.